Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs [Financial Post (Toronto, Ontario, Canada)]
Psyence Biomedical Ltd. - Ordinary Shares (PBM)
Company Research
Source: Financial Post
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence Group pursuant to a debt-for-equity swap agreement NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc. (“ Psyence Group “) (CSE: PSYG) today announced the successful closing of its previously announced disposal of its 11.13% stake in privately held PsyLabs to its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“ PBM ” or “ Psyence Biomed “) (“ Disposal “). Per the terms of the Disposal, Psyence Biomed will issue to Psyence Group 2,000,000 shares of its common stock. PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development. As previously announced, Psyence Biomed and PsyLabs have an existing strategic partnership whereby PsyLabs has granted P
Show less
Read more
Impact Snapshot
Event Time:
PBM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBM alerts
High impacting Psyence Biomedical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PBM
News
- Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialGlobeNewswire
- Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial [Yahoo! Finance]Yahoo! Finance
- Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations [Canadian Business Journal (Canada)]Canadian Business Journal
- Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligationsGlobeNewswire
PBM
Sec Filings
- 12/20/24 - Form F-1
- 12/19/24 - Form 6-K
- 12/18/24 - Form 6-K
- PBM's page on the SEC website